317 related articles for article (PubMed ID: 31818845)
21. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
[TBL] [Abstract][Full Text] [Related]
22. Phase I open-label trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study): study protocol.
Vatandoust S; Bright T; Roy AC; Watson D; Gan S; Bull J; Abbas MN; Karapetis CS
BMJ Open; 2019 May; 9(5):e026732. PubMed ID: 31061042
[TBL] [Abstract][Full Text] [Related]
23. Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in colorectal carcinoma at high risk of peritoneal carcinomatosis: short-term and long-term outcomes from the CHECK study - protocol for a randomised, multicentre, phase 3 trial.
Pacelli F; Gerardi C; Rulli E; Abatini C; Rotolo S; Garattini S; Melotti G; Torri V; Galli F; Rulli E; Di Giorgio A;
BMJ Open; 2022 Aug; 12(8):e051324. PubMed ID: 35914916
[TBL] [Abstract][Full Text] [Related]
24. Hyperthermic intraperitoneal chemotherapy using a combination of mitomycin C,5-fluorouracil, and oxaliplatin in patients at high risk of colorectal peritoneal metastasis: A Phase I clinical study.
Shimizu T; Sonoda H; Murata S; Takebayashi K; Ohta H; Miyake T; Mekata E; Shiomi H; Naka S; Tani T
Eur J Surg Oncol; 2014 May; 40(5):521-528. PubMed ID: 24388411
[TBL] [Abstract][Full Text] [Related]
25. Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.
Chemama S; Bayar MA; Lanoy E; Ammari S; Stoclin A; Goéré D; Elias D; Raynard B; Antoun S
Ann Surg Oncol; 2016 Nov; 23(12):3891-3898. PubMed ID: 27352205
[TBL] [Abstract][Full Text] [Related]
26. Peritoneal Carcinomatosis in Colorectal Cancers - Management Perspective Needs a Change.
Bhandare M; Patil P; Pai V; Bhamre R; Engineer R; Ostwal V; Saklani A
Clin Colorectal Cancer; 2017 Jun; 16(2):e1-e6. PubMed ID: 27670895
[TBL] [Abstract][Full Text] [Related]
27. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
[TBL] [Abstract][Full Text] [Related]
28. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
Cashin PH; Mahteme H; Spång N; Syk I; Frödin JE; Torkzad M; Glimelius B; Graf W
Eur J Cancer; 2016 Jan; 53():155-62. PubMed ID: 26751236
[TBL] [Abstract][Full Text] [Related]
29. Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study.
van der Kaaij RT; Braam HJ; Boot H; Los M; Cats A; Grootscholten C; Schellens JH; Aalbers AG; Huitema AD; Knibbe CA; Boerma D; Wiezer MJ; van Ramshorst B; van Sandick JW
JMIR Res Protoc; 2017 Jul; 6(7):e136. PubMed ID: 28705789
[TBL] [Abstract][Full Text] [Related]
30. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P
J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286
[TBL] [Abstract][Full Text] [Related]
31. Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin.
Nagourney RA; Evans S; Tran PH; Nagourney AJ; Sugarbaker PH
Eur J Surg Oncol; 2021 Apr; 47(4):738-742. PubMed ID: 33004272
[TBL] [Abstract][Full Text] [Related]
32. Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial.
Murono K; Nagata H; Ishimaru K; Emoto S; Kaneko M; Hiyoshi M; Sasaki K; Otani K; Shuno Y; Nishikawa T; Tanaka T; Hata K; Kawai K; Nozawa H; Muro K; Ishihara S
Cancer Chemother Pharmacol; 2019 Jan; 83(1):145-150. PubMed ID: 30386886
[TBL] [Abstract][Full Text] [Related]
33. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Kuijpers AM; Mehta AM; Aalbers AG; van Driel WJ; Boot H; Verwaal VJ
Eur J Surg Oncol; 2014 Aug; 40(8):937-42. PubMed ID: 24630923
[TBL] [Abstract][Full Text] [Related]
34. Peritoneal metastases from colorectal cancer: patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Riss S; Mohamed F; Dayal S; Cecil T; Stift A; Bachleitner-Hofmann T; Moran B
Eur J Surg Oncol; 2013 Sep; 39(9):931-7. PubMed ID: 23810280
[TBL] [Abstract][Full Text] [Related]
35. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J
Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial.
Klaver CE; Musters GD; Bemelman WA; Punt CJ; Verwaal VJ; Dijkgraaf MG; Aalbers AG; van der Bilt JD; Boerma D; Bremers AJ; Burger JW; Buskens CJ; Evers P; van Ginkel RJ; van Grevenstein WM; Hemmer PH; de Hingh IH; Lammers LA; van Leeuwen BL; Meijerink WJ; Nienhuijs SW; Pon J; Radema SA; van Ramshorst B; Snaebjornsson P; Tuynman JB; Te Velde EA; Wiezer MJ; de Wilt JH; Tanis PJ
BMC Cancer; 2015 May; 15():428. PubMed ID: 26003804
[TBL] [Abstract][Full Text] [Related]
37. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
[TBL] [Abstract][Full Text] [Related]
38. Survival prognostic factors in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy: a single institution experience.
Nikolic S; Dzodic R; Zegarac M; Djurisic I; Gavrilovic D; Vojinovic V; Kocic M; Santrac N; Radlovic P; Radosavljevic D; Pupic G; Martinovic A
J BUON; 2014; 19(1):66-74. PubMed ID: 24659645
[TBL] [Abstract][Full Text] [Related]
39. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin.
Cravioto-Villanueva A; Cavazos M; Luna-Perez P; Martinez-Gomez H; Ramirez ML; Solorzano J; Montiel H; Esquivel J
Surg Today; 2016 Aug; 46(8):979-84. PubMed ID: 27138212
[TBL] [Abstract][Full Text] [Related]
40. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin.
Witkamp AJ; de Bree E; Kaag MM; Boot H; Beijnen JH; van Slooten GW; van Coevorden F; Zoetmulder FA
Eur J Cancer; 2001 May; 37(8):979-84. PubMed ID: 11334722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]